Venetoclax in adult acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) often presents with poor prognosis, especially in patients intolerant to intensive chemotherapy.
• B-cell lymphoma-2 (BCL-2) is a key protein in cancer cell survival, making it a target for novel therapies.
• Venetoclax, a BCL-2 inhibitor, has shown promise in preclinical and clinical settings for AML.

Purpose of the Study:

• To review the current landscape of venetoclax-based therapy in AML.
• To discuss the efficacy of venetoclax as monotherapy and in combination regimens.
• To highlight areas for future research, including optimal dosing, sequencing, and biomarker identification.

Main Methods:

• Review of preclinical studies involving AML cell lines and xenograft models.
• Analysis of clinical trial data for venetoclax in AML patients.
• Synthesis of existing literature on venetoclax mechanisms and clinical outcomes.

Main Results:

• Venetoclax demonstrates significant antileukemic activity in AML.
• Effective in patients with unfavorable prognoses and those unsuitable for intensive chemotherapy.
• Shows efficacy both as a single agent and in combination therapies.

Conclusions:

• Venetoclax represents a revolutionary therapeutic option for specific AML patient populations.
• Optimal venetoclax dosing, sequencing, and combination strategies require further investigation.
• Biomarker discovery is essential for predicting treatment response and resistance to venetoclax in AML.